drugset / Trial / NCT02507284
Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease
Phase 2
Completed
106 enrolled
Azevan Pharmaceuticals
National Institute of Neurological Disorders and Stroke (NINDS) · collabNeuroNEXT Network · collab
RandomizedSequentialQuadruple-blindTreatment
Summary
This study evaluates the tolerability, safety and activity of SRX246 in the treatment of irritability in patients with Huntington's disease. Two-thirds of all participants will receive SRX246, while the other third will receive a placebo.
Timeline
- Start
- 2016-05-10
- Primary completion
- 2018-09-10
- Completion
- 2018-12-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SRX246 | Small molecule | 120 mg | Oral |
| Subject | SRX246 | Small molecule | 160 mg | Oral |